Properties (58)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
C1 esterase inhibitor
|
| gptkbp:administrativeDivision |
every 3 to 4 days
|
| gptkbp:availability |
prescription only
|
| gptkbp:clinicalTrials |
improved quality of life
Phase III ongoing studies preventive treatment recommended for HAE patients reduced frequency of attacks shown in clinical trials |
| gptkbp:community_service |
available
|
| gptkbp:contraindication |
thromboembolic events
anaphylaxis hypersensitivity_to_C1_esterase_inhibitor |
| gptkbp:customerFeedback |
generally positive
|
| gptkbp:date |
2008-10-07
|
| gptkbp:dosageForm |
solution
1 mL/min |
| gptkbp:drugInterdiction |
none reported
injectable solution half-life of 3-4 days increases C1 inhibitor levels |
| gptkbp:formulation |
human plasma-derived
|
| gptkbp:hasCapacity |
available through manufacturer
|
| gptkbp:hasCompetitors |
other HAE treatments
|
| gptkbp:hasPopulation |
adults and children
|
| gptkbp:healthcare |
important for adherence
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cinryze
|
| gptkbp:is_monitored_by |
C1 inhibitor levels
|
| gptkbp:isSubjectTo |
10 mL
|
| gptkbp:label |
risk of hypersensitivity reactions
risk of thromboembolic events |
| gptkbp:mandates |
gptkb:hereditary_angioedema
|
| gptkbp:manufacturer |
ViroPharma
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:marketSegment |
ongoing
|
| gptkbp:offers |
varies by region
|
| gptkbp:packaging |
single-use vial
|
| gptkbp:receives_funding_from |
available in many insurance plans
|
| gptkbp:regulatoryCompliance |
FDA_approved
EMA_approved Health_Canada_approved |
| gptkbp:research |
various sources
|
| gptkbp:researchFocus |
improving efficacy
reducing side effects |
| gptkbp:route |
intravenous
|
| gptkbp:safetyFeatures |
required
|
| gptkbp:sideEffect |
headache
nausea abdominal pain diarrhea |
| gptkbp:storage |
refrigerated
|
| gptkbp:supplyChain |
managed by manufacturer
|
| gptkbp:training |
required for patients
|
| gptkbp:usedFor |
prevention of hereditary angioedema attacks
|